NCT01894386View on ClinicalTrials.gov

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 15, 2013

Primary Completion Date

September 26, 2013

Study Completion Date

September 26, 2013

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

FF 400 mcg

100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)

DRUG

UMEC 500 mcg

125 mcg powder for inhalation delivered by DPI

DRUG

UMEC 250 mcg

62.5 mcg powder for inhalation delivered by DPI

DRUG

VI 100 mcg

25 mcg powder for inhalation delivered by DPI

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01894386 - Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses | Biotech Hunter | Biotech Hunter